Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization
Louis Chupak(Bristol-Myers Squibb (United States)), Susan Wee(Bristol-Myers Squibb (United States)), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Robert G. Gentles(Bristol-Myers Squibb (United States)), Scott Martin(Bristol-Myers Squibb (United States)), John S. Tokarski(Bristol-Myers Squibb (Germany)), Christopher B. Allard(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Xiaofan Zheng(Blood Center of Zhejiang Province), Jianliang Shi(Bristol-Myers Squibb (United States)), Carolyn Cao(Bristol-Myers Squibb (United States)), Min Ding(Jiangsu University), Jie Fang(Chinese Academy of Sciences), Michael Wichroski(Bristol-Myers Squibb (Germany))
Cited by 21
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
|Nature Communications|2020|432
Inhibition of Activator Protein-1, NF-κB, and MAPKs and Induction of Phase 2 Detoxifying Enzyme Activity by Chlorogenic Acid
|Journal of Biological Chemistry|2005|388
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239